SHINGRIX

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Visual of the SHINGRIX creative campaign.

RECOMMENDATIONS FROM NACI & CIQ

The National Advisory Committee on Immunization (NACI) recommends that SHINGRIX should be offered to adults 50 years of age and older (strong recommendation). 2
According to NACI, a strong recommendation applies to most individuals and should be followed unless a clear and compelling rationale for an alternative approach is present. 2
Refer to the NACI statement on the Public Health Agency website for further information.
The Comité sur l'immunisation du Québec (CIQ) preferentially recommends SHINGRIX for adults 50 years of age and older. 3‡

SHINGRIX is indicated for the prevention of herpes zoster (HZ, or shingles) in adults 50 years of age or older. 1

HELP PROTECT YOUR PATIENTS AGED 50+ FROM SHINGLES 1

Visual of the two components of the SHINGRIX vaccine.

Mechanism of Action

SHINGRIX is the first shingles vaccine to combine a non-live antigen with an Adjuvant System*

SHINGRIX is designed to induce cellular and humoral immune responses to VZV. 1

Learn about the components of SHINGRIX

Efficacy data

The efficacy of SHINGRIX was studied in 2 phase III trials with 29,305 patients 1

Vaccine efficacy (VE) was studied in subjects ≥50 years old (ZOE-50) and subjects ≥70 years old (ZOE-70). 1

Learn more about the efficacy of SHINGRIX

Dosing and Administration

2-dose series 1

Non-live SHINGRIX is for intramuscular injection, given as a 2-dose series. 1

Learn how to reconstitute and administer SHINGRIX

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Canada/shingrix_scientific_rationale_en_04_sept_19_v2.mp4

Scientific Rationale Video

The Scientific Rationale Video provides an engaging and easily understood look into the science behind the development of SHINGRIX.

Contraindications:

Patients with a known hypersensitivity to the active substance or to any component of the vaccine.

Most serious warnings and precautions:

Administration: Do not administer the vaccine intravascularly, intradermally or subcutaneously.

Other relevant warnings and precautions:

A protective immune response may not be elicited in all vaccinees
Not for prevention of primary varicella infection or treatment of HZ or postherpetic neuralgia
Postpone in those with acute severe febrile illness
Use with caution in those with thrombocytopenia or any coagulation disorder
Syncope following or before any vaccination as a psychogenic response
Fever and shivering were more frequent when the 23-valent pneumococcal polysaccharide (PPV23) vaccine was coadministered with SHINGRIX
Use in special populations such as pregnant or nursing women or pediatrics (<18 years of age) has not been established
Limited data in immunocompromised adults 50 years of age or older

Adverse events:

Solicited local and general adverse reactions that occurred in clinical trials within 7 days of vaccination in subjects aged 50–69 and ≥70 years respectively were: pain (85.6%, 69.2%), redness (38.5%, 37.7%), swelling at the injection site (28.5%, 23.0%), myalgia (53.0%, 35.1%), fatigue (51.3%, 36.6%), headache (45.2%, 29.0%), shivering (33.1%, 19.5%), fever (25.9%, 14.3%), gastrointestinal symptoms (20.5%, 13.5%)
Unsolicited adverse reactions that occurred in clinical trials within 30 days of vaccination in ≥1% of subjects and ≥2-fold higher than placebo recipients included chills (3.5%), injection site pruritus (2.2%), and malaise (1.7%)
Post-market adverse reactions are hypersensitivity reactions (rare), including rash, urticaria, angioedema

For more information

Please consult the product monograph at gsk.ca/SHINGRIX/PM for important information relating to dosing and administration, adverse reactions, contraindications and drug interactions which have not been discussed in this piece. To request a product monograph, or to report an adverse event please call 1-800-387-7374.

* Clinical significance has not been established.
† Modified Total Vaccinated Cohort (mTVC) was the primary efficacy analysis and included all subjects randomized in the study who received a second dose of the vaccine and did not develop a confirmed case of shingles within one month after the second dose.
‡ Reproduction of information from the PIQ, 7th ed. Zona-SU section; http://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/
The original French version of this information was published in 2018 by the Department of Health and Social Services. The Dept. declines any responsibility for any damage, loss or injury that may result from this translation into English. In case of contradiction between the English and French versions of this information, the latter it will prevail. The Government of Quebec is and remains the only copyright owner of the work in French. The English version has not been validated by the Ministry of Health and Social Services.

References:

SHINGRIX Product Monograph. GlaxoSmithKline Inc., June 3, 2020.
Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html.
Zona-SU : vaccin sous unitaire contre le zona. Ministère de la Santé et Services sociaux Québec. https://www.msss.gouv.qc.ca/professionnels/vaccination/piq-vaccins/zona-su-vaccin-sous-unitaire-contre-le-zona/. Updated June 20, 2018. Accessed July 9, 2018.

Français

Unit for Hours:H

Unit for Minutes: M

Loading text: $loading

Filter redirection page URL: events.html

Filter Tags:Medical indications|Products|Therapy Areas

Filter Tags values when filtered by all Tags:All Medical indications|All Products|All Therapy Areas

OutofBox filter category name:Format

Filter Reset all button text:Reset All

Filter Apply button text:Apply

Events registration success message: Registration successfull

Events registration failure message: Registration failure

Events un-registration success message: Un-Registration successfull

Events un-registration failure message: Un-Registration failure

Reset all default value: false

Show More Naivagation Values: 10|15|20

Previous Text label: Previous

Next Text label: Next

Show Text label: Show

Seats left Text: spaces left

No Seats left Text: No spaces left

Text Area Blank copy in Email Template:Not Provided

ASYEVE0001=Event Registration-Portal
ASYEVE0002=Watched General Video
ASYEVE0003=Watched Virtual Rep Video
ASYEVE0004=Watched Patient Video
ASYEVE0005=Watched Expert Video
ASYEVE0006=Watched Webcast
ASYEVE0007=Downloaded Content-Portal
ASYEVE0008=Clicked to App Store
ASYEVE0009=Watched Learning Module Video
ASYEVE0010=Email Sent
ASYEVE0011=Email Read
ASYEVE0012=Email Clicked
ASYEVE0013=Shared a Link
ASYEVE0014=Rep Request
ASYEVE0015=Joined health.gsk
ASYEVE0016=Email not sent